As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
7 Analysts have issued a Finch Therapeutics Group Inc forecast:
7 Analysts have issued a Finch Therapeutics Group Inc forecast:
| Jun '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -20 -20 |
72%
72%
|
|
| EBIT (Operating Income) EBIT | -20 -20 |
74%
74%
|
|
| Net Profit | -14 -14 |
90%
90%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in September 2017 and is headquartered in Somerville, MA.
| Head office | United States |
| CEO | Matthew Blischak |
| Employees | 1 |
| Founded | 2014 |
| Website | finchtherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


